How a “common essential” gene can still hide a selective weakness
MTAP deletion can make cancer cells more sensitive to PRMT5 inhibition, even though PRMT5 is broadly essential to proliferating cells. The story is a lesson in how the kind of genetic screen used can conceal a biomarker signal.
Written retrospectively and published on August 3, 2026.
Background reading, not clinical guidance. This describes published research; it is not a recommendation for any individual case, and the cited studies may have been superseded.
Synthetic lethality describes a situation in which two disruptions together are far more damaging than either alone. Three independent studies in 2016 found that deletion of MTAP, often co-deleted with CDKN2A, can increase dependence on the methyltransferase PRMT5.
The subtlety is that PRMT5 is not a dependency unique to MTAP-deleted tumours. It is broadly required by proliferating cells and appears on DepMap lists of common essential genes. MTAP deletion appears to create a partly inhibited state that may widen a therapeutic window, rather than inventing the dependency from nothing.
Why the screen matters
A complete CRISPR knockout can make a gene look pan-lethal and obscure a selective biomarker association. RNA interference partially suppresses genes instead; analyses comparing the approaches identified PRMT5 as an example where the MTAP signal becomes visible with partial suppression.
That is a methodological warning, not a claim that an earlier filter literally discarded the original PRMT5 discovery. The initial finding came from RNAi-based screens. Clinical validation is still early, and no PRMT5 inhibitor was FDA-approved as of July 2026.
Comments
Threads are public and indexed — please keep personal medical data out of them. Found a clinical error? Open an issue instead.
Comments are not switched on yet — the backend still needs to be configured.